Related Experiment Videos
Prophylactic indomethacin: systematic review and meta-analysis
1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Insights
Prophylactic indomethacin shows immediate benefits for premature infants, reducing patent ductus arteriosus and intraventricular hemorrhage. However, long-term effects and adverse events require further investigation before routine use.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Clinical Trials
Background:
- Premature infants (<1750g) are at high risk for patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH).
- Prophylactic indomethacin is used to prevent these complications, but its overall effectiveness and safety profile require thorough evaluation.
Purpose of the Study:
- To assess the efficacy of prophylactic intravenous indomethacin in minimizing mortality and morbidity associated with PDA and IVH in low birth weight infants.
- To synthesize evidence from randomized controlled trials on the impact of prophylactic indomethacin.
Main Methods:
- Comprehensive literature search of Medline, Embase, and Oxford Database of Perinatal Trials (1980-present).
- Inclusion of 14 randomized controlled trials based on strict eligibility criteria.
- Independent assessment of study quality and data extraction by two observers.
- Meta-analysis techniques employed to pool results and estimate treatment effects.
Main Results:
- A trend towards reduced neonatal mortality was observed with prophylactic indomethacin.
- Significant reduction in symptomatic patent ductus arteriosus (PDA) incidence (RD -0.217, 95% CI -0.275 to -0.160).
- Significant reduction in grades 3 and 4 intraventricular hemorrhage (IVH) incidence (RD -0.039, 95% CI -0.066 to -0.011).
- No significant effect on respiratory outcomes.
- Potential transient impairment of renal function and a trend towards increased necrotizing enterocolitis noted.
- Insufficient data on long-term neurodevelopmental outcomes.
Conclusions:
- Prophylactic indomethacin offers immediate benefits in reducing PDA and IVH in high-risk infants.
- Further research is necessary to evaluate long-term adverse effects and neurodevelopmental outcomes.
- Routine recommendation for prophylactic indomethacin is pending comprehensive data on safety and long-term efficacy.
Aims:
To examine the effectiveness of prophylactic intravenous indomethacin in reducing the mortality and morbidity associated with patent ductus arteriosus and intraventricular haemorrhage in infants weighing less than 1750 g at birth.
Methods:
A literature search from 1980 onwards was made of three databases: Medline; Embase; and the Oxford Database of Perinatal Trials. Using strict criteria applied to randomised controlled trials only, two observers independently selected 14 studies for inclusion in the review. The methodological quality of each study was assessed independently by two observers using explicit criteria. Data on relevant outcome measures were extracted on two separate occasions. Where appropriate, the results of individual trials were combined using meta-analysis techniques to provide a pooled estimate of effect.
Results:
There is a trend towards reduced neonatal mortality in infants receiving prophylactic indomethacin, pooled estimate of risk difference -0.025 (95% confidence interval (CI) -0.061, 0.010). The incidence of symptomatic patent ductus arteriosus is significantly reduced in treated infants, pooled estimate of risk difference -0.217 (95% CI -0.275, -0.160), but there is no evidence that treatment affects respiratory outcomes. Prophylactic indomethacin significantly reduces the incidence of grades 3 and 4 intraventricular haemorrhage in treated infants, pooled estimate of risk difference -0.039 (95% CI -0.066, -0.011). However, there is no sound evidence assessing the long term effect of prophylaxis on neurodevelopmental outcome. Although there is a trend in treated infants towards an increased incidence of necrotising enterocolitis, pooled estimate of risk difference 0.015 (95% CI -0.002, 0.033), and some evidence that treatment may transiently impair renal function, there is no evidence that haemostasis is disturbed.
Conclusion:
Prophylactic treatment with indomethacin has several immediate benefits. However, more data are needed on the incidence of possible adverse effects and neurodevelopmental outcomes before routine use of this therapy can be recommended.